Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Assessment of adults with cognitive impairment being evaluated for Alzheimer disease (AD) and other causes of cognitive impairment.
Measurement of beta-amyloid (1-42)(Abeta42), total-Tau, and phosphorylated-Tau (p-Tau) in cerebrospinal fluid (CSF) is useful in the differential diagnosis of Alzheimer Disease (AD) and other causes of cognitive impairment.
These assays are being proposed as an alternative/adjunct to imaging studies to assess AD pathology.
The p-Tau/Abeta42 ratio provides excellent concordance with amyloid positron emission tomography (PET) scan to assess the presence of amyloid deposition in patients with AD.
Electrochemiluminescent Immunoassay